Mackenzie L. Bevry, PharmD, identifies the key populations that currently have evidence for improved outcomes with pre-emptive pharmacogenomic testing, describes the difference between clinical and direct-to-consumer pharmacogenomic testing, recognizes some of the currently available pharmacogenomic testing options available to patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.